Albumin-bound paclitaxel (nab-paclitaxel), in combination with gemcitabine, is used for first-or second-line treatment of advanced pancreatic cancer (APC). The objectives of this retrospective single institution study are to report the rates of hematologic toxicity, febrile neutropenia (FN), growth factor utilization, progression-free and overall survival of nab-paclitaxel-gemcitabine in a real-world, non-clinical trial setting. Patients with APC treated with nab-paclitaxel-gemcitabine between January 1, 2012 and December 31, 2014 were identified. Data were retrospectively collected from the electronic medical record under an institutional IRB-approved protocol. A total of 29 patients treated with nab-paclitaxel-gemcitabine were included in the analyses. Half of the patients (52%) had received previous therapy for advanced disease, with the majority of those patients (80%) receiving FOLFIRINOX. Grade ≥3 neutropenia and thrombocytopenia were reported in 31% and 21% of patients. FN was observed in 1 patient (3%), and growth factor was utilized in 10% of patients. Most patients (86%) required at least one dose modification, with 76% of patients having dose omission due to toxicity. Median progression-free survival was 3.9 months and median overall survival was 5.4 months. Our results suggest that the rates of hematologic toxicity in the real-world setting are similar to those seen in clinical trial population, despite variances in clinical practice. It remains unclear whether the underutilization of growth factor support affects the incidence of neutropenia outside of clinical trials. The short overall and progression-free survival observed in this study population are not unexpected, as the majority of patients received nab-paclitaxel-gemcitabine as second-line therapy.
Introduction
Pancreatic cancer is expected to become the second leading cause of cancer death in United States by 2020. Over 80% of newly diagnosed patients will have locally advanced or metastatic disease. This confers a poor prognosis, with a 5-year survival of 2.3% and median overall survival of 6 months (National Cancer Institute, 2014; American Cancer Society, 2014; Rahib et al, 2014) .
In 2011, the treatment paradigm for pancreatic cancer changed with the publication of the landmark study evaluating combination chemotherapy consisting of oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) , and the publication of phase 1-2 data demonstrating clinical activity of nab-paclitaxel-gemcitabine in advanced pancreatic cancer patients. One limitation to these regimens was the high incidence of hematologic toxicity. The reported rates of Grade ≥3 neutropenia and thrombocytopenia in the FOLFIRINOX study were 45.7% and 9.1%, respectively; and the reported rates of Grade ≥3 neutropenia and thrombocytopenia in the phase 1-2 nab-paclitaxel-gemcitabine study were 75% and 28% (Conroy et al., 2011; von Hoff et al., 2011) .
In 2013, von Hoff and colleagues published the results of a pivotal phase 3 clinical trial, known as the MPACT study, which compared nab-paclitaxel plus gemcitabine to gemcitabine monotherapy. Patients treated with nab-paclitaxel-gemcitabine had a median overall survival (OS) of 8.5 months compared to 6.7 months with gemcitabine alone (p<0.001). The median progression-free survival (5.5 vs. 3 months, p<0.001) and response rate (27% vs. 7%, p<0.001) were significantly improved in the nab-paclitaxel-gemcitabine group. With respect to hematologic toxicity, nab-paclitaxelgemcitabine had higher rates of Grade ≥3 neutropenia, leukopenia, and thrombocytopenia compared with gemcitabine alone (Table 1) (von Hoff et al., 2013) . The notable differences in observed hematologic toxicity rates between the phase 1-2 and MPACT studies may be related to the use of granulocyte stimulating factor (G-CSF) in the latter, as well as, the introduction of protocol-specified dose reductions. As shown in Table 1 , in the MPACT study approximately onequarter of patients treated with nab-paclitaxel-gemcitabine utilized G-CSF support (von Hoff et al., 2013) . Von Hoff and colleagues (2013) do not comment on the indications for G-CSF use (i.e. primary vs. secondary prophylaxis); however, upon further review of final published protocol dose modification tables, the investigators recommended the use of G-CSF after day 15 if patients had therapy withheld or required dose modifications on day 8. The use of G-CSF was also suggested if day 15 labs indicated decreased counts (ANC <1000 cells/mm3 or platelets <75K cells/mm3). In the instance of isolated thrombocytopenia (without neutropenia), or febrile neutropenia, G-CSF was also permissible (von Hoff et al., 2013) Following FDA approval of nab-paclitaxel-gemcitabine for metastatic pancreatic cancer, the utilization of this regimen significantly and expectedly increased at the University of Virginia Health System. It quickly became apparent that a dose adjustment strategy for hematologic toxicity would be necessary to minimize dose delays and maximize dose intensity. The nab-paclitaxel prescribing information provides complex tables of dose modifications. (Celgene Corporation, 2013) . At our institution, these dose modifications tables are used for guidance for dose adjustments due to toxicity from nab-paclitaxel-gemcitabine. Notably absent from the prescribing information dose modification table are recommendations on the use of granulocyte stimulating factor (G-CSF). The discordance between clinical trial design and current clinical practice may increase risk for hematologic toxicity and/or febrile neutropenia, as well as decrease dose intensity and clinical efficacy. The purpose of this retrospective observational study is to assess the safety and tolerability of nab-paclitaxel-gemcitabine at a single academic medical center in a real-world, nonclinical trial setting. 
Methods
This was a retrospective observational study evaluating the safety and tolerability of nabpaclitaxel-gemcitabine for locally advanced or metastatic pancreatic adenocarcinoma. Prior to study initiation, the University of Virginia Institutional Review Board approved the study.
Adult patients at least 18 years of age treated with nab-paclitaxel-gemcitabine between January 1, 2012, and November 30, 2014 at the University of Virginia Health System (UVaHS) and affiliated community practice sites were identified through the electronic medical record (EMR). Patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma were included. Patients were excluded if they were participating in a clinical trial with nab-paclitaxel and gemcitabine or if they received nab-paclitaxel-gemcitabine in the adjuvant or neoadjuvant setting. Data were collected including: patient demographics, ECOG performance status, location of primary tumor, presence of liver metastases, use of previous therapy (including surgery, radiation, and chemotherapy), laboratory tests, chemotherapy doses and dates of treatment, reason for dose modification, treatment interruption and discontinuation, date of progression, date of death (if applicable), location of treatment (academic medical center vs. affiliated community clinic), and use of G-CSF therapy.
The primary endpoints of this study were the rates of Grade ≥3 neutropenia and Grade ≥3 thrombocytopenia during treatment with nab-paclitaxel-gemcitabine. Secondary endpoints included the rates of Grade ≥3 leukopenia and febrile neutropenia. All toxicities were defined according to NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0) definitions. Median progression-free survival and overall survival; dose intensity and dose density; median time to onset of neutropenia, thrombocytopenia and febrile neutropenia; median time to first dose modification, rate of hospitalization secondary to neutropenic fever; rate of antibacterial prophylaxis, rate of growth factor use and type of growth factor use (filgrastim vs. pegfilgrastim, and primary prophylaxis vs. secondary prophylaxis) were also collected. Dose intensity was defined as the proportion of cumulative administered dose relative to the planned cumulative dose. Dose density was defined as the proportion of doses administered on time relative to the total number of administered doses. Progression was defined per physician assessment as stated in EMR clinic note.
Fisher's exact test was used to compare rates of hematologic toxicity and growth factor utilization at UVaHS to those reported in MPACT study. Descriptive statistics were used to analyze the primary and secondary endpoints. A Kaplan-Meier survival analysis was conducted on the population as a whole to assess real-world use of this regimen. The statistical software programs, SPSS (version 20.0 for Windows; SPSS, Inc; Chicago, IL) and SAS 9.4 (SAS Institute, Cary, NC), were used to perform statistical analyses.
Results
A total of 31 patients were treated at UVaHS and affiliated community clinics between January 1, 2012 and December 31, 2014 with nab-paclitaxel-gemcitabine for locally advanced unresectable or metastatic pancreatic adenocarcinoma. Twenty-nine patients met inclusion criteria and were included in the study analysis. Two patients were excluded, (one patient used this regimen in the adjuvant setting, and the other received the majority of treatment outside of the institution (Fig. 1) .
Fig. 1. Patients evaluated for analysis

Patients characteristics
Characteristics of the study patients are described in study patients received surgery, radiation or chemotherapy as previous treatment for their disease, with 52% of the population patients receiving prior therapy for the treatment of advanced disease. The most commonly used regimen for first-line treatment of advanced disease was FOLFIRINOX (41%). The majority of patients were treated in the academic medical center (62%) while the remaining 38% of patients were treated in the affiliated community sites. Growth factor use* 3 (10) 110 (26) 0.08 *9 patients at UVaHS qualified for G-CSF use per MPACT study protocol
Toxicities and survival
As depicted in Table 3 , the incidence of neutropenia (31 vs. 38%, p=0.55) and thrombocytopenia (21 vs. 13%, p=0.25) at UVaHS was not statistically different compared with the MPACT clinical trial The incidence of grade ≥3 febrile neutropenia in our study population was identical to the reported incidence in the MPACT study (3%). There was a trend toward less growth factor support provided to the patients in the real-world setting compared to clinical trial study population (10 vs. 28%, p=0.08). However, 9 patients at UVaHS qualified for G-CSF use per MPACT study protocol but did not receive it. The median overall survival was 5.4 months; and median progression-free survival was 3.9 months ( Fig. 2 and Fig. 3 ). Fig. 3 Kaplan-Meier analysis of progression-free survival Patients received a median of 3 cycles of nab-paclitaxel-gemcitabine with a range of 1 to 12 cycles. The median duration of treatment was 2.2 months. The median initial starting doses of nabpaclitaxel-gemcitabine were identical to those provided in the nab-paclitaxel package insert (125 mg/m 2 for nab-paclitaxel and 1000 mg/m2 for gemcitabine). The average dose density achieved of nab-paclitaxel and gemcitabine were 75% and 96% respectively. The relative dose intensity for nab-paclitaxel and gemcitabine were 67% and 75%, respectively. Twenty-four patients (83%) had treatment discontinuation. The most common reasons for discontinuation included deteriorated performance status and progressive disease.
Fig. 2. Kaplan-Meier analysis of overall survival
Administered treatment and dose modification
Of the 29 patients in this study, 25 patients (86%) required at least one dose modification and 22 patients (76%) had a least one dose omission. Of the 78 doses that required modification, 38 (49%) were modified per the nab-paclitaxel package insert or MPACT trial protocol recommendation tables. Forty doses (51%) were modified per physician discretion, using a non-standard dose reduction or omission strategy. Table 4 outlines the documented reasons for dose omission. Interestingly, 22 of the doses held at UVaHS (47%) would have been administered if the MPACT study protocol dosing table was followed.
Discussion
This is the first study to our knowledge examining hematologic toxicity of nab-paclitaxelgemcitabine outside of a clinical trial after the MPACT trial in U.S. patients with pancreatic adenocarcinoma. Nab-paclitaxel-gemcitabine appears to have taken the role as second-line therapy for patients who have progression on FOLFIRINOX, or as first-line therapy in those who may not tolerate FOLFIRINOX due to older age and/or poor performance status.
Interestingly, the incidence of grade ≥3 neutropenia was comparable to what was reported in the MPACT trial. This may be related to lower relative dose intensity of nab-paclitaxel administered at our institution. Based on previously reported data, nab-paclitaxel is thought to contribute more to the high rates of neutropenia in this regimen, whereas gemcitabine more likely contributes to thrombocytopenia (von Hoff et al., 2013; Gradishar et al., 2009; Coleman et al., 2011; Burris III et al., 1997) . Our study findings support this hypothesis, as gemcitabine dose density and intensity were high at 96% and 72% respectively, and the incidence of grade ≥3 thrombocytopenia, though not significantly different, appeared to trend higher than what was observed in the MPACT trial. Additionally, the non-significant lower rates of grade ≥3 neutropenia observed in this study may be the result of decreased nab-paclitaxel dose intensity compared with the MPACT trial (67 vs. 81%).
The rate of febrile neutropenia reported in the phase 1-2 study of nab-paclitaxel-gemcitabine (2%) did not support the addition of growth factor support in the MPACT trial; however, 25% of patients in the MPACT trial were given G-CSF (von Hoff et al., 2011; von Hoff et al., 2013 , von Hoff et al., 2014 . The indications for G-CSF use in that study were not defined, but due to the low rate of febrile neutropenia (1%) it was likely secondary to isolated grade ≥3 neutropenia on day 8 or 15 of treatment. The use of G-CSF may have allowed for increased dose intensity and dose density. In the present study, the rate of growth factor support was 50% less than the MPACT trial, but the direct effects on hematologic toxicity and other clinical outcomes remain unclear.
The median overall survival and progression-free survival observed in our study's real-world evaluation of this regimen were less than those observed in the MPACT trial (Von Hoff et al., 2013) . This is not surprising as the study populations varied with respect to previous treatment of metastatic disease. In our review, half of the patients were receiving nab-paclitaxel-gemcitabine as second-line treatment of locally advanced or metastatic disease, whereas the MPACT trial Hoff et al., 2013) . A previously published comprehensive analysis of second-line therapy for advanced pancreatic cancer reported median overall and progression-free survivals of 6 months and 2.9 months, respectively, which is consistent with our study findings (Rahma et al., 2013) . However, the studies analyzed in this comprehensive review did not include the regimen of nab-paclitaxelgemcitabine, since the study was conducted and published prior to the FDA approval of this regimen in pancreatic cancer.
The majority of our patients required dose reduction or omission of nab-paclitaxel-gemcitabine, which resulted in less than planned dose intensity and density. The impact of reduced dose density and intensity on clinical efficacy are unclear. Interestingly, a retrospective "real world" study of 61 patients treated with the more complex FOLFIRINIOX regimen reported a high rate of modifications (58%) (Peddi et al., 2012) . This resulted in a lower incidence of grade ≥3 neutropenia (19.7%) when compared landmark FOLFIRINOX study (47.5%), but there was no meaningful impact on overall survival (Peddi et al., 2012; von Hoff et al., 2013) .
In an effort to decrease the hematologic toxicity with the nab-paclitaxel-gemcitabine regimen, the weekly schedule had been modified to every other week in some institutions. A team of oncologists at The Ohio State University retrospectively evaluated 63 patients for toxicity and 47 patients for response following the administration of every other week nab-paclitaxel-gemcitabine as first-line therapy for metastatic pancreatic cancer (Krishna et al., 2015) . Median overall survival (11.1 months) and progression-free survival (5.5 months) were comparable to the MPACT study, while rates of grade ≥3 neutropenia and thrombocytopenia were much lower (10% and 3%, respectively). Growth factor was also utilized much less (8%) with every other week dosing compared with MPACT (Krishna et al., 2015) . Despite the retrospective nature of study, the clinical implications of their study findings are likely to impact the future of nab-paclitaxel-gemcitabine dosing schema.
There were many limitations to the present study including its small sample size, precluding exploratory subgroup analyses. Additionally, the baseline characteristics (i.e. previous treatment of metastatic disease) of this patient population are different from the MPACT study, limiting a comparison of clinical outcomes. The incidence of non-hematologic toxicity was not assessed in this study due to its retrospective nature.
Conclusion
Our results suggest rates of hematologic toxicity in the real-world, non-clinical trial setting are similar to those seen in study populations, despite variances in clinical practice. It remains unclear if the underutilization of growth factor support affects the incidence of neutropenia outside of clinical trials. Future clinical trials with this regimen should assess the necessity of growth factor use, since it is not common practice outside the clinical trial setting. Our institution's use of nabpaclitaxel-gemcitabine as a second-line therapy and/or in those with decreased performance status likely accounts for the lower overall survival and progression-free survival compared with the MPACT study. The optimal sequencing of FOLFIRINOX and nab-paclitaxel for advanced pancreatic adenocarcinoma has been not studied and warrants further investigation.
